I Gozes

Summary

Affiliation: Tel Aviv University
Country: Israel

Publications

  1. ncbi NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    CNS Drug Rev 11:353-68. 2005
  2. ncbi NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell
    Illana Gozes
    Department of Human Molecular Genetic and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 4:507-9. 2007
  3. ncbi A novel VIP responsive gene. Activity dependent neuroprotective protein
    I Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Ann N Y Acad Sci 921:115-8. 2000
  4. ncbi Tau pathology and future therapeutics
    I Gozes
    Laboratory for Molecular Neuroendocrinology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 7:685-96. 2010
  5. ncbi Addressing Alzheimer's disease tangles: from NAP to AL-108
    Illana Gozes
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Levi Edersheim Gitter Institute for Functional Brain Imaging, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 6:455-60. 2009
  6. ncbi NAP accelerates the performance of normal rats in the water maze
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    J Mol Neurosci 19:167-70. 2002
  7. ncbi VIP, from gene to behavior and back: summarizing my 25 years of research
    Illana Gozes
    Adams Super Center for Brain Studies, The Dr Diana and Zelman Elton Elbaum Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv, Israel
    J Mol Neurosci 36:115-24. 2008
  8. ncbi Microtubules (tau) as an emerging therapeutic target: NAP (davunetide)
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Curr Pharm Des 17:3413-7. 2011
  9. ncbi Activity-dependent neuroprotective protein: from gene to drug candidate
    Illana Gozes
    The Adams Super Center for Brain Studies and Levi Edersheim Gitter fMRI Institute, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv 69978, Israel
    Pharmacol Ther 114:146-54. 2007
  10. ncbi Tau as a drug target in Alzheimer's disease
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Mol Neurosci 19:337-8. 2002

Collaborators

Detail Information

Publications97

  1. ncbi NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    CNS Drug Rev 11:353-68. 2005
    ..NAP is poised for further clinical development targeting several indications, including Alzheimer's disease...
  2. ncbi NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell
    Illana Gozes
    Department of Human Molecular Genetic and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 4:507-9. 2007
    ..This data demonstrates that NAP functions as a neuroprotectant, at least in part, through its interaction with tubulin with a resulting increase in microtubule assembly...
  3. ncbi A novel VIP responsive gene. Activity dependent neuroprotective protein
    I Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Ann N Y Acad Sci 921:115-8. 2000
    ..We suggest that ADNP may be part of the VIP protection pathway through the femtomolar-acting NAP and through putative interaction with other macromolecules...
  4. ncbi Tau pathology and future therapeutics
    I Gozes
    Laboratory for Molecular Neuroendocrinology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 7:685-96. 2010
    ....
  5. ncbi Addressing Alzheimer's disease tangles: from NAP to AL-108
    Illana Gozes
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Levi Edersheim Gitter Institute for Functional Brain Imaging, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 6:455-60. 2009
    ..The following article reviews NAP's discovery and pharmacological characterization that has led to clinical development of a novel tangle-directed drug candidate...
  6. ncbi NAP accelerates the performance of normal rats in the water maze
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    J Mol Neurosci 19:167-70. 2002
    ..These results suggest efficacy for NAP in normal aging that is associated with accumulating environmental and genetic toxic factors...
  7. ncbi VIP, from gene to behavior and back: summarizing my 25 years of research
    Illana Gozes
    Adams Super Center for Brain Studies, The Dr Diana and Zelman Elton Elbaum Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv, Israel
    J Mol Neurosci 36:115-24. 2008
    ..This review cites only articles that I have coauthored and gives my own perspective of this exciting ever-growing field...
  8. ncbi Microtubules (tau) as an emerging therapeutic target: NAP (davunetide)
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, School of Neuroscience, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Curr Pharm Des 17:3413-7. 2011
    ..Based on these extensive preclinical results, davunetide (NAP) is now being evaluated in a Phase II/III study of the tauopathy, progressive supranuclear palsy (PSP); (Allon Therapeutics Inc.)...
  9. ncbi Activity-dependent neuroprotective protein: from gene to drug candidate
    Illana Gozes
    The Adams Super Center for Brain Studies and Levi Edersheim Gitter fMRI Institute, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv 69978, Israel
    Pharmacol Ther 114:146-54. 2007
    ..In this respect, structure-activity studies have identified a short 8 amino acid peptide in ADNP/NAPVSIPQ (NAP) that provides potent neuroprotection. NAP is currently in clinical development for neuroprotection...
  10. ncbi Tau as a drug target in Alzheimer's disease
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Mol Neurosci 19:337-8. 2002
  11. ncbi VIP and drug design
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Curr Pharm Des 9:483-94. 2003
    ..VIP-based drug design is discussed below...
  12. ncbi The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury
    Illana Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Curr Alzheimer Res 2:149-53. 2005
    ..The increase in ADNP in injured brains is now suggested to be a part of an endogenous compensatory mechanism and NAP treatment provides an additional protection. Toxicology studies suggest NAP as safe for further clinical development...
  13. ncbi The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection
    Illana Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Alzheimers Dis 6:S37-41. 2004
    ..The findings described here may open up new horizons in research and development of neuroprotective compounds...
  14. ncbi Neuroscience collaborations meeting report: the Israel Society for Neuroscience, and the Institute of Neurosciences, Mental Health and Addiction in Canada, first joint meeting, Sunday, Dec. 15, 2002, Eilat, Israel
    Illana Gozes
    The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978 Israel
    J Mol Neurosci 21:55-6. 2003
  15. ncbi From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Mol Neurosci 20:315-22. 2003
    ....
  16. ncbi Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Best Pract Res Clin Endocrinol Metab 18:623-40. 2004
    ..Overexpression of VIP has been associated with diarrhea and cancer, and overexpression of VIP receptors is associated with cancerous growth. This short review outlines some of the recent progress made in VIP research...
  17. ncbi Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 3:197-9. 2006
    ..These short peptides hold promise in future neuroprotective/neurotrophic drug development. Clinical development of NAP is currently in progress by Allon Therapeutics, Inc...
  18. ncbi Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 32:428-31. 2011
    ..Daily intranasal NAP treatment significantly decreased hyperactivity in STOP-deficient mice and protected visual memory, supporting further clinical development...
  19. ncbi Neuroprotective peptide drug delivery and development: potential new therapeutics
    I Gozes
    Dept of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Trends Neurosci 24:700-5. 2001
    ....
  20. ncbi Protection against developmental deficiencies by a lipophilic VIP analogue
    I Gozes
    Dept Clin Biochem Sackler Med Sch Tel Aviv Univ, Israel
    Neurochem Res 23:689-93. 1998
    ..SNV may act by providing neuroprotection, thereby improving cognitive functions. This work is dedicated to Prof. R.J. Wurtman whose inspiration and leadership in the field of neuroscience and cognition is beyond comparison...
  21. ncbi Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility
    I Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
    Ann N Y Acad Sci 865:266-73. 1998
    ..The structure-activity studies suggest that the methionine in position 17 and the first six amino acids are important in the determination of PACAP activity, knowledge that may facilitate PACAP-based drug design...
  22. ncbi Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design
    I Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel 69978, USA
    Proc Natl Acad Sci U S A 96:4143-8. 1999
    ..Thus, lipophilic peptide fragments offer bioavailability and stability, providing lead compounds for drug design against neurodegenerative diseases...
  23. ncbi Pharmaceutical VIP: prospects and problems
    I Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Curr Med Chem 6:1019-34. 1999
    ..VIP-based drug design and non-invasive innovative delivery modes are discussed with emphasis on tumor diagnosis and treatment, impotence treatment and neuroprotection...
  24. ncbi A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein
    I Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
    Ann N Y Acad Sci 897:125-35. 1999
    ..ADNP, a potential mediator of VIP-associated neuronal survival, and the new peptide, a potential lead compound for drug design, are discussed below...
  25. ncbi NAP mechanisms of neuroprotection
    Illana Gozes
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Mol Neurosci 24:67-72. 2004
    ..This paper identifies p53, a key regulator of cellular apoptosis, as an intracellular target for NAP's activity...
  26. ncbi Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Pharm Des 17:2603-12. 2011
    ..These studies associate neuroprotection in vivo and in vitro and provide a broad base for future drug development based on NAP and D-SAL against multiple neurodegenerative conditions...
  27. ncbi A new concept in the pharmacology of neuroprotection
    I Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
    J Mol Neurosci 14:61-8. 2000
    ..These femtomolar-acting peptides form a basis for a new concept in pharmacology: femtomolar neuroprotection...
  28. ncbi Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze
    I Gozes
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
    J Pharmacol Exp Ther 293:1091-8. 2000
    ..The small size of the molecules, the low dosage required, the noninvasive administration route, and the demonstrated activity in a relevant paradigm suggest NAP as a lead compound for future drug design...
  29. ncbi Neuropeptides: brain messengers of many faces
    I Gozes
    Dept of Clinical Biochemnistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Trends Neurosci 24:687-90. 2001
    ..6-11 May 2001 with Satellite Symposium, Israeli-French Symposium, Israel Ministry of Science, Culture and Sport, 6 May 2001, held at Maale Hachmicha and Tel Aviv University, Israel...
  30. ncbi NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)
    Illana Gozes
    Department of Human Molecular Genetic and Biochemistry, Sackler School of Medicine, Tel Aviv University, Einstein Street, Tel Aviv 69978, Israel
    BMC Neurosci 9:S3. 2008
    ..The beta amyloid peptide interacts with microtubules, and previous studies have demonstrated protection against beta amyloid (25-35) toxicity by NAP and ADNF-9. NAP also inhibits beta amyloid (25-35 and 1-40) aggregation...
  31. ncbi Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide
    M Bassan
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
    J Neurochem 72:1283-93. 1999
    ....
  32. ncbi Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures
    O Ashur-Fabian
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, 69978, Tel Aviv, Israel
    Neurosci Lett 307:167-70. 2001
    ..Thus, NO may mediate part of the cell-cell interaction and natural maintenance activity of VIP/SNV/NAP, while cGMP may mediate neuroprotection...
  33. ncbi VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress
    R A Steingart
    Department of Clinical Biochemistry, Sackler Medical School, Tel Aviv University, Israel
    J Mol Neurosci 15:137-45. 2000
    ..Furthermore, addition of an ADNF-9 antibody prevented the ability of VIP to protect against oxidative stress, suggesting that VIP protection is partially mediated via an ADNF-like protein...
  34. ncbi Cloning and characterization of the human activity-dependent neuroprotective protein
    R Zamostiano
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Biol Chem 276:708-14. 2001
    ..Thus, ADNP is implicated in maintaining cell survival, perhaps through modulation of p53...
  35. ncbi The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line
    M Bassan
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
    Neurosci Lett 250:37-40. 1998
    ..Essentially no extracellular LDH activity was detected, indicating no cellular damage. A novel aspect for stress proteins having extracellular protective roles is suggested...
  36. ncbi A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines
    E Gelber
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Cancer 92:2172-80. 2001
    ..Combination therapy with the lipophilic VIP analog SNH and the preferred chemotherapeutic agent may greatly enhance the response rate, and by permitting a dose reduction, should significantly reduce side effects...
  37. ncbi A VIP hybrid antagonist: from developmental neurobiology to clinical applications
    I Gozes
    Department of Clinical Biochemistry, Tel Aviv University, Israel
    Cell Mol Neurobiol 15:675-87. 1995
    ..The hybrid antagonist inhibited VIP-stimulated mitosis in whole embryo cultures and in a variety of cancer cell lines in vitro and in vivo, suggesting therapeutical potential...
  38. ncbi Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress
    R A Steingart
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Mol Cell Endocrinol 252:148-53. 2006
    ..ADNP expression was previously shown to oscillate as a function of the estrus cycle in the mouse arcuate nucleus, these oscillations are now correlated with increased cellular protection...
  39. ncbi Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease
    D Offen
    Department of Clinical Biochemistry and Felsentein Medical Research Center, Rabin Medical Center, The Sackler Faculty of Medicine, Tel Aviv University, Israel
    Brain Res 854:257-62. 2000
    ..Our data suggest these compounds as potential lead compounds for protective therapies against Parkinson's disease...
  40. ncbi A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication
    Inna Divinski
    Department of Clinical Biochemistry and Interdepartmental Core Facility, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Biol Chem 279:28531-8. 2004
    ....
  41. ncbi PolyADP-ribosylation is involved in neurotrophic activity
    Leonid Visochek
    The Neufeld Cardiac Research Institute, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Neurosci 25:7420-8. 2005
    ..A fast loosening of the highly condensed chromatin structure by polyADP-ribosylation of histone H1, which renders DNA accessible to transcription and repair, may underlie the role of polyADP-ribosylation in neurotrophic activity...
  42. ncbi Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP
    Margalit Zusev
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Regul Pept 123:33-41. 2004
    ..In conclusion, VIP, PACAP and the VPAC2 receptor may all contribute to the regulation of ADNP gene expression in the developing astrocyte...
  43. ncbi The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide
    Osnat Ashur-Fabian
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 24:1413-23. 2003
    ..Further assays showed biotin-NAP binding to Abeta. These results suggest that part of the neuroprotective mechanism exerted by NAP is through modulation of toxic protein folding in the extracellular milieu...
  44. ncbi The influence of the peptide NAP on Mac-1-deficient mice following closed head injury
    Roy Zaltzman
    Department of Clinical Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 26:1520-7. 2005
    ..Obviously, this plasticity in gene expression is intimately interwoven with the genetic background of the animal. NAP treatment tilts the balance toward neuroprotection...
  45. ncbi Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model
    Inna Vulih-Shultzman
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Pharmacol Exp Ther 323:438-49. 2007
    ..NAP treatment partially ameliorated cognitive deficits and reduced tau hyperphosphorylation in the ADNP(+/-) mice. NAP is currently in phase II clinical trials assessing effects on mild cognitive impairment...
  46. ncbi A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis
    Jacob Romano
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    J Mol Neurosci 18:37-45. 2002
    ..Thus, Mac-1 is suggested as a marker for the long-term outcome of head injury and as a potential target for NAP protective actions...
  47. ncbi Peptide neuroprotection through specific interaction with brain tubulin
    Inna Divinski
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neurochem 98:973-84. 2006
    ..Thus, the underlying mechanism for the neuroprotection offered by NAP is targeting neuronal microtubules that are essential for neuronal survival and function...
  48. ncbi Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress
    Michal Kushnir
    Department of Human Molecular Genetics and Biochemistry, Sacker Medical School, Tel Aviv University, Tel Aviv, Israel
    J Neurochem 105:537-45. 2008
    ..These findings represent an initial characterization of ADNP2 and suggest that this gene product may have an important function in brain by playing a role in cellular survival pathways...
  49. ncbi ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance
    Shmuel Mandel
    Department of Human Molecular Genetics and Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv, 69978, Israel
    J Mol Neurosci 35:127-41. 2008
    ..These results position ADNP in direct association with neuronal cell differentiation and maturation...
  50. ncbi NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia
    Michael Rotstein
    The Institute for Child Development and the Pediatric Neurology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Pharmacol Exp Ther 319:332-9. 2006
    ..ApoE-deficient mice show a greater susceptibility to hypoxic damage and better response to NAP treatment...
  51. ncbi NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Israel
    Neurobiol Dis 34:381-8. 2009
    ..The current studies show for the first time activity for NAP in a "pure" tauopathy model, positioning it as a promising drug candidate in multiple neurodegenerative tauopathies...
  52. ncbi Activity-dependent neuroprotective protein: a novel gene essential for brain formation
    Albert Pinhasov
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel
    Brain Res Dev Brain Res 144:83-90. 2003
    ..In conclusion, ADNP is identified here as a new key gene essential for organogenesis in the developing embryo and may be implicated as a clinical target associated with proper neurodevelopment...
  53. ncbi The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy
    Ilona Zemlyak
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neurochem 111:1252-63. 2009
    ..These data suggest that NAP may provide neuroprotection in one of the most serious neurological conditions, epilepsy...
  54. ncbi NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia
    Avia Merenlender-Wagner
    The Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 31:1368-73. 2010
    ..Daily intranasal NAP treatment significantly decreased hyperactivity in the STOP+/- mice and protected visual memory...
  55. ncbi NAP protects against cyanide-related microtubule destruction
    Ilona Zemlyak
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neural Transm 116:1411-6. 2009
    ..Although the primary site of action of cyanide is considered to be the mitochondria, the current results involve microtubule destruction by cyanide toxicity that is completely reversed by NAP treatment...
  56. ncbi Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo
    Eliezer Giladi
    Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv, 69978, Israel
    J Mol Neurosci 33:278-83. 2007
    ..These results showed that VIP regulated brain ADNP expression in a regionally specific manner and indicated that both maternal and offspring VIP genotype may influence ADNP expression in the brain...
  57. ncbi The effects of vascular intrauterine growth retardation on cortical astrocytes
    Haim Bassan
    Pediatric Neurology and Child Development Unit, Dana Children s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Matern Fetal Neonatal Med 23:595-600. 2010
    ..We sought to determine the pathogenesis of neurodevelopmental impairments in survivors of intrauterine growth retardation (IUGR)...
  58. ncbi Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults
    Roy Zaltzman
    Department of Clinical Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel
    Neuroreport 14:481-4. 2003
    ..Furthermore, NAP treatment resulted in decreased mRNA expression of the inflammation marker, Mac-1. Thus, a potentially new prophylactic treatment against neurodegeneration is suggested...
  59. ncbi The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay
    Haim Bassan
    The Institute for Child Development and Pediatric Neurology, Division of Pediatrics, Dana Children s Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Hypertens Pregnancy 24:201-11. 2005
    ..IUGR neonates experience higher mortality, and the surviving infants have a higher incidence of neurological and intellectual impairment...
  60. ncbi Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze
    Roy N Alcalay
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Neurosci Lett 361:128-31. 2004
    ..It is concluded that NAP offers a unique combination of anxiolytic/cognitive enhancing properties observed after prolonged chronic intranasal treatment...
  61. ncbi VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target
    Inbar Pilzer
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Peptides 27:2867-76. 2006
    ..Parallel assays demonstrated that VIP increased cAMP accumulation in COS-7 cells expressing hop2. These results support the hypothesis that hop2 mediates the cytoprotective effects attributed to VIP...
  62. ncbi Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina
    David Dangoor
    Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Einstein Street, 69978 Tel Aviv, Israel
    Peptides 26:2579-84. 2005
    ..The expression pattern of neuropeptide receptors in the female sexual organs suggest an intimate involvement of the corresponding neuropeptides in female sexual function...
  63. ncbi NAP protects against cytochrome c release: inhibition of the initiation of apoptosis
    Ilona Zemlyak
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Eur J Pharmacol 618:9-14. 2009
    ..As cytochrome c release is a known initiator of the apoptotic pathway, it is suggested that NAP inhibits the early events of apoptosis...
  64. ncbi In vitro and in vivo treatment of colon cancer by VIP antagonists
    Albert Levy
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Regul Pept 109:127-33. 2002
    ..Thus, neurotensin(6-11)VIP(7-28) could serve as an effective cancer treatment and a preventing agent...
  65. ncbi Brain injury-dependent expression of activity-dependent neuroprotective protein
    Roy Zaltzman
    Department of Clinical Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv 69978, Israel
    J Mol Neurosci 24:181-7. 2004
    ..05) in ADNP mRNA expression was detected in the injured cerebral hemisphere 29 d post-CHI. The data presented may be associated with ADNP's crucial involvement in brain development and response to injury...
  66. ncbi Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL
    Miri Holtser-Cochav
    Human Molecular Genetics and Biochemistry, Sackler Medical School, Tel Aviv University, Israel
    J Mol Neurosci 28:303-7. 2006
    ..The identification of tubulin as a target binding site for NAP-related peptides explains, in part, the broad neuroprotective activity offered by these potent peptides...
  67. ncbi The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase
    Yoram Wollman
    Department of Nephrology, Tel Aviv Medical Center, 64239, Tel Aviv, Israel
    Regul Pept 108:175-7. 2002
    ..These results suggest that membrane endopeptidases modulate VIP-associated cell proliferation and enhancement of endopeptidase activity may serve as a target for cancer therapy...
  68. ncbi Novel analogs of VIP with multiple C-terminal domains
    David Dangoor
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Einstein Street, Tel Aviv 69978, Israel
    Peptides 28:1622-30. 2007
    ..Therefore, it is concluded that the association between the VIP ligand to the VIP receptor could be tolerable to size increases in the C-terminal region of the VIP ligand and multiplication of the C-terminal does not increase activity...
  69. ncbi Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis
    Shmuel Mandel
    Department of Human Molecular Genetics and Biochemistry, Tel Aviv University, Tel Aviv 69978, Israel
    Dev Biol 303:814-24. 2007
    ..These results place ADNP at a crucial point of gene regulation, repressing potential endoderm genes and enhancing genes associated with organogenesis/neurogenesis...
  70. ncbi Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability
    David Dangoor
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Pept Sci 14:321-8. 2008
    ....
  71. ncbi A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes
    Ruth A Steingart
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Life Sci 71:2543-52. 2002
    ..Thus, the HOX A4 and the Oct-3 homeobox genes may partially mediate SNH activity on cancer cells...
  72. ncbi Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus
    Sharon Furman
    Department of Clinical Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Neurosci Lett 373:73-8. 2005
    ..The results presented here suggest that ADNP has a part in the estrus cycle as an affecter or an effector...
  73. ncbi PolyADP-ribosylation is required for long-term memory formation in mammals
    Shmuel Goldberg
    The Neufeld Cardiac Research Institute and Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neurochem 111:72-9. 2009
    ..These findings implicate PARP-1 activation in molecular processes underlying long-term memory formation during learning...
  74. ncbi Novel extended and branched N-terminal analogs of VIP
    David Dangoor
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Einstein Street, Tel Aviv 69978, Israel
    Regul Pept 137:42-9. 2006
    ..However, increased receptor binding was not directly associated with increased cAMP production suggesting steric dynamic interactions...
  75. ncbi NAP protects hippocampal neurons against multiple toxins
    Ilona Zemlyak
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Peptides 28:2004-8. 2007
    ..In summary, we have significantly expanded previous findings in demonstrating here direct neuroprotective effects for NAP on vital hippocampal neurons that are key participants in cognitive function in vivo...
  76. ncbi Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex
    Shmuel Mandel
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    J Biol Chem 282:34448-56. 2007
    ..These morphological changes are closely associated with the SWI/SNF complex multifunctionality. Taken together, the current study uncovers a molecular basis for the essential function of the ADNP gene and protein...
  77. ncbi A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model
    Tal Shprung
    Department of Human Molecular Genetics and Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv, 69978, Israel
    J Mol Neurosci 37:254-62. 2009
    ..This new method should enable further assessment of microtubule-interacting drugs and other cytoskeletal components for their potential influence of mitochondrial movement as a test for activity and side effects...
  78. ncbi A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes
    Inbar Pilzer
    Department of Molecular Genetics and Biochemistry, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Dr Diana and Zelman Elton Elbaum Laboratory for Molecular Neuroendocrinology, Tel Aviv University, Tel Aviv 69978, Israel
    Ann N Y Acad Sci 1070:484-90. 2006
    ..The present article introduces PAC1(3a) that was originally discovered in testes as another potential regulator in rat astrocytes...
  79. ncbi NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death
    Ronen R Leker
    Department of Neurology, Agnes Ginges Center for Human Neurogenetics, Hebrew University Hadassah Medical School, University Hospital, Jerusalem, Israel
    Stroke 33:1085-92. 2002
    ..Activity-dependent neuroprotective protein mediates some of the protective effects of vasoactive intestinal peptide. The neuroprotective NAP sequence is derived from activity-dependent neuroprotective protein...
  80. ncbi NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function
    Francisco J Quintana
    Department of Medical Biochemistry and Molecular Biology, The University of Seville School of Medicine, Avda. Sanchez Pizjuan, 4, 41009 Sevilla, Spain
    Ann N Y Acad Sci 1070:500-6. 2006
    ..These findings indicate that ADNP/NAP can play an important role in immune regulation as well as in neuroprotection, which may be mutually related processes...
  81. ncbi Complex array of cytokines released by vasoactive intestinal peptide
    Douglas E Brenneman
    Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
    Neuropeptides 37:111-9. 2003
    ..In summary, subnanomolar concentrations of VIP released a complex array of cytokines from astrocytes that may contribute to the mitogenic and neurotrophic properties of this neuropeptide in the central nervous system...
  82. ncbi The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro
    Wolf A Lagrèze
    Eye Hospital, Albert Ludwig Universität, Freiburg, Germany
    Invest Ophthalmol Vis Sci 46:933-8. 2005
    ..We evaluated these findings in cultures of purified rat retinal ganglion cells (RGCs) using two such peptides: ADNF-9 and NAP. In a second step, the influence of these peptides on neurite outgrowth in retinal explants was investigated...
  83. ncbi Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding
    Jolanta B Zawilska
    Centre for Medical Biology, Polish Academy of Sciences, 93 232 Lodz, Poland
    J Mol Neurosci 25:215-24. 2005
    ..In addition, the observed stronger action of PACAP (both PACAP38 and PACAP27), when compared to any form of VIP, on cAMP production in this tissue, suggests its interaction with both PAC1 and VPAC receptors...
  84. ncbi NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis
    Jorge Busciglio
    Department of Neurobiology and Behavior, University of California, Irvine, CA 92697, USA
    Curr Pharm Des 13:1091-8. 2007
    ....
  85. ncbi Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures
    Virginia L Smith-Swintosky
    CNS Research, Johnson and Johnson Pharmaceutical Research and Development, LLC, Spring House, PA 19447 0776, USA
    J Mol Neurosci 25:225-38. 2005
    ..These results suggest that ADNF-9 and NAP might contribute to neuronal plasticity associated with development and repair after injury...
  86. ncbi Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage
    Yasuji Matsuoka
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    J Mol Neurosci 31:165-70. 2007
    ..Our results indicate that NAP treatment of transgenic mice initiated at an early stage reduced both Abeta and tau pathology, suggesting that NAP might be a potential therapeutic agent for AD...
  87. ncbi Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry
    Joanna M Hill
    Laboratory of Developmental Neuroscience, NICHD, NIH, Bethesda, MD 21029, USA
    J Mol Neurosci 31:183-200. 2007
    ..In conclusion, impaired VIP activity during mouse embryogenesis resulted in permanent changes to both adult brain chemistry/cell biology and behavior with aspects of autism-like social deficits...
  88. ncbi Protective peptides that are orally active and mechanistically nonchiral
    Douglas E Brenneman
    Section of Developmental and Molecular Pharmacology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
    J Pharmacol Exp Ther 309:1190-7. 2004
    ..These studies suggest therapeutic potential for the combined administration of neuroprotective peptides that can act through a mechanism independent of chiral recognition...
  89. ncbi A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease
    Yasuji Matsuoka
    Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Road N W, Washington, DC 20057, USA
    J Pharmacol Exp Ther 325:146-53. 2008
    ..Our results suggest that neuronal microtubule interacting agents such as NAP may be useful therapeutic agents for the treatment or prevention of tauopathies...
  90. ncbi Antagonism of VIP-stimulated cyclic AMP formation in chick brain
    Jerzy Z Nowak
    Institute of Biogenic Amines, Polish Academy of Sciences, P 225 90 950 Lodz, Poland
    J Mol Neurosci 20:163-72. 2003
    ..Unlike truncated PACAP, the NT-VIP hybrid peptides tested may represent VPACtype receptor-selective blocking activity...
  91. ncbi Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection
    Illana Gozes
    J Mol Neurosci 24:333-6. 2004
  92. ncbi Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein
    Youssef Sari
    Indiana University School of Medicine, Department of Anatomy and Cell Biology, Neuroscience Programs, 635 Barnhill Drive, MS5035, Indianapolis, IN 46202, USA
    Brain Res Rev 52:107-18. 2006
    ..Here, we discuss the many aspects of alcohol-associated growth restriction in the developing brain and the potential inhibition of this severe phenotype through the use of neuroprotective peptides...
  93. ncbi Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development
    Sarah H Poggi
    Department of Obstetrics and Gynecology, 3PHC, Georgetown University Hospital, 3800 Reservoir Road, Washington, DC, USA
    Am J Obstet Gynecol 187:973-6. 2002
    ..The objective of this study was to characterize ADNP in mouse embryonic tissues throughout development...
  94. ncbi The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley
    Illana Gozes
    Expert Opin Ther Targets 11:733-6. 2007
    ..Professor Gozes directs a very active research laboratory at Tel Aviv University and is mentoring and has mentored directly approximately 50 graduate students toward their MSc or PhD degrees...
  95. ncbi Summer neuropeptide conference. The 3rd joint meeting of the summer neuropeptide conference (13th annual meeting) and the European Neuropeptide Club (13th annual meeting) Montauk, NY, June 8-12, 2003
    Illana Gozes
    Neuropeptides 37:157-8. 2003
  96. ncbi (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist
    Terry W Moody
    National Cancer Institute, Medicine Branch, Rockville, MD 20850, USA
    J Mol Neurosci 18:29-35. 2002
    ..Also, the increase in cAMP caused by VIP using CHO cells transfected with VPAC1 or VPAC2 receptors was antagonized by (SN)VIPhyb. These results indicate that (SN)VIPhyb is an antagonist for VPAC1, VPAC2, and PAC1 receptors...
  97. ncbi Apolipoprotein E knockout mice as a model of behavioral dysfunction
    Illana Gozes
    J Mol Neurosci 23:149-50. 2004